Year: 2021

JERSEY CITY, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) — AvePoint, Inc. (NASDAQ: AVPT), the largest data management solutions provider for Microsoft 365, today announced financial results for the third quarter ended September 30, 2021.  “AvePoint delivered its eleventh consecutive record quarter with total revenue of $54 million and 79% year over year growth in subscription revenue for our SaaS and data management platform,” said Dr. Tianyi Jiang (TJ), CEO and Co-Founder, AvePoint. “With most companies still in the early stages of their SaaS optimization and multi-cloud shifts, there is a massive market opportunity for AvePoint to manage and protect digital collaboration data on a recurring basis that will only increase as companies’ SaaS operations become more mature and complex.” Third Quarter 2021 Financial...

~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ Announced proof-of-mechanism data from first three PiMZ subjects dosed in Phase 1 Part B study evaluating ZF874 for the treatment of Alpha-1 Antitrypsin Deficiency (“AATD”) ~ ~ Announced collaboration between Orexia Therapeutics and Schrödinger to discover novel orexin receptor agonists ~ ~ Successful entry into a $300 million financing facility with Oberland Capital to enable further scale-up of development activities and pursuit of strategic business development opportunities ~ ~ Centessa leadership team strengthened through appointment...

LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022 LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on track to begin enrolling later this quarter LAVA-051 granted orphan drug designation by the U.S. FDA for the treatment of CLL Cash and investments of $142 million as of Sept. 30, 2021UTRECHT, The Netherlands and PHILADELPHIA, Nov. 15, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced financial results for the third quarter ended Sept. 30, 2021 and recent corporate highlights. “This was a transformational quarter for LAVA,”...

Q3 2021 Core EBITDA increased 91% year over year to $7.0 million 2021 EBITDA Guidance Increased to $26 MillionEnding Serviced Deposits increased 118% year over year to $2 billion RADNOR, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) — BM Technologies Inc. (NYSE American: BMTX) (“BM Technologies,” “BMTX,” “we,” or the “Company”) one of the largest digital banking platforms in the country, today reported record results for the three and nine months ended September 30, 2021. THIRD QUARTER FINANCIAL HIGHLIGHTSQ3 2021 revenues increased 20% to $22.0 million from $18.3 million in Q3 2020. Q3 2021 net income increased to $8.8 million from $250,000 in Q3 2020. Q3 2021 net income includes a $6.0 million noncash gain on the revaluation of the private warrant liability. Q3 2021 core earnings1 were $2.8 million in Q3 2021, or $0.23 per diluted share,...

CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announced today its financial and operating results for the third quarter 2021. THIRD QUARTER 2021 FINANCIAL RESULTS (Unaudited, stated in Canadian dollars except per share and unit data)  Three months ended September 30,   Nine months ended September 30,  For the   2021     2020     2021     2020      ($)     ($)     ($)     ($)  Revenue   1,644,314     1,066,851     4,376,745     6,587,045  Gross Profit (Loss)   38,298     (442,261 )   (52,954 )   1,507,868  Loss for the period   (453,744 )   (961,869 )   (2,212,845 )   (943,927 )Gross profit (loss) as a percentage of revenue   2 %   (41 %)   (1 %)   23 %         Loss per share        Basic $ (0.02 ) $ (0.04 ) $ (0.08 ) $ (0.03 )Diluted $ (0.02 ) $ (0.04 ) $ (0.08 ) $ (0.03 )     As...

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update. “The third quarter was transformative for Indaptus as we successfully closed the merger with Decoy Biosystems, Inc. (“Decoy”) and completed a $30 million private placement to support our exciting new clinical programs,” said Jeffrey Meckler, Chief Executive Officer of Indaptus. “We are executing to our strategy of advancing Decoy20 as a potential new treatment modality for a variety of cancer indications with unmet medical need. Our goal to enter the clinic with Decoy20 in 2022 remains on track, however, we now plan to file the IND next year as we are in the process of recruiting...

CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the third quarter ended September 30, 2021. Third Quarter Highlights:In July 2021, the Company released top line Phase 2 clinical trial results from its development partner, Newsoara, that showed a 1.1-day improvement in GI recovery in patients receiving LB1148 vs placebo.In July 2021, the Company entered a worldwide exclusive license with the University of California to patent rights covering certain engineered substrates and use in measuring degradative enzymes for disease conditions, including...